Access
To read this article in full you will need to log-in or choose from the options on the right.
Targets and Mechanisms - Autoimmune disease
SciBX 2(25); doi:10.1038/scibx.2009.996
Published online June 25 2009
Extra navigation
Proteasome progress
by Lev Osherovich, Senior Writer
Researchers at Proteolix have found a small molecule that inhibits a subunit of the proteasome involved in immune cell activation. The compound's profile could make it suitable for autoimmune indications, an area previously off-limits to general proteasome inhibitors because of toxicity concerns.
To read this article in full you will need to log-in or choose from the options on the right.
